日本转移性肾细胞癌患者医疗水平的改善
Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma.
作者信息
Fujiwara Ryo, Komai Yoshinobu, Oguchi Tomohiko, Numao Noboru, Yamamoto Shinya, Yonese Junji, Yuasa Takeshi
机构信息
Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
出版信息
Cancer Diagn Progn. 2022 Jan 3;2(1):25-30. doi: 10.21873/cdp.10072. eCollection 2022 Jan-Feb.
BACKGROUND/AIM: To evaluate the relationship between treatment period and overall survival (OS) and to identify clinical factors associated with OS in patients with metastatic renal cell carcinoma (mRCC).
PATIENTS AND METHODS
Two hundred thirteen consecutive patients with mRCC receiving systemic therapy between 2008 and 2020 were divided into two groups: those starting first-line therapy in 2008-2015 (n=133) and those in 2016-2020 (n=80). Clinical factors associated with OS were retrospectively and statistically analyzed.
RESULTS
Median OS and one-, three- and five-year OS rates were not reached and 88.7%, 64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and 34.2% in 2008-2015 (p=0.0013). Multivariate analysis identified the period in which first-line therapy was started as the strongest predictor for OS (p=0.0002).
CONCLUSION
OS was significantly better in mRCC patients treated in 2016-2020 than in 2008-2015. Treatment period was the strongest predictor for OS.
背景/目的：评估治疗时间与总生存期（OS）之间的关系，并确定转移性肾细胞癌（mRCC）患者中与OS相关的临床因素。
患者与方法
将2008年至2020年间连续接受全身治疗的213例mRCC患者分为两组：2008 - 2015年开始一线治疗的患者（n = 133）和2016 - 2020年开始一线治疗的患者（n = 80）。对与OS相关的临床因素进行回顾性统计分析。
结果
2016 - 2020年治疗的患者未达到中位OS以及1年、3年和5年OS率，分别为88.7%、64.9%和64.9%；2008 - 2015年治疗的患者中位OS为31.4个月，1年、3年和5年OS率分别为78.5%、42.8%和34.2%（p = 0.0013）。多因素分析确定一线治疗开始的时间是OS的最强预测因素（p = 0.0002）。
结论
2016 - 2020年治疗的mRCC患者的OS明显优于2008 - 2015年治疗的患者。治疗时间是OS的最强预测因素。
Zotero 插件